Kamada Expands Specialty Plasma Collection with New Texas Facility to Meet Growing Healthcare Demands

Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapeutics, is strategically expanding its plasma collection capabilities with the launch of a new 11,100-square-foot facility in San Antonio, Texas. The center represents a significant investment in addressing critical medical needs through specialized plasma collection.

The new facility is designed to support up to 50 donor beds and is projected to collect approximately 50,000 liters of plasma annually. Once fully operational, the center is expected to generate between $8 million and $10 million in annual revenue through the sale of normal source plasma to pharmaceutical manufacturers.

Hyper-immune plasma plays a crucial role in medical treatments, containing high concentrations of specific antibodies used to prevent and treat various serious conditions. These include protecting organ transplant recipients, treating hepatitis B infections, and preventing potentially fatal diseases like rabies. By developing its own plasma collection infrastructure, Kamada aims to reduce dependency on third-party suppliers and potentially lower raw material costs.

The company is currently seeking approvals from the U.S. Food and Drug Administration and the European Medicines Agency, with anticipated clearance expected within nine to twelve months of application submission. This expansion follows Kamada's previous plasma collection site openings in Beaumont and Houston, Texas.

Kamada's strategic approach involves leveraging its six FDA-approved plasma-derived therapeutics to address rare and underserved medical conditions. The San Antonio facility represents a significant step in the company's mission to become a leading provider of specialty plasma-derived treatments, potentially improving medical outcomes for patients worldwide.